Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Mayzent

Mayzent 0.25 mg film-coated tablets Mayzent 1 mg film-coated tablets Mayzent 2 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11

HOS-140765 · Präparat HOS-098578

During treatment initiation siponimod should not be concomitantly used in patients receiving class Ia (e.g. quinidine, procainamide) or class III (e.g. amiodarone, sotalol) anti-arrhythmic medicinal products, QT-prolonging medicinal products with known arrhythmogenic properties, heart-rate-lowering calcium channel blockers (such as verapamil or diltiazem) or other substances that may decrease heart rate (e.g. ivabradine or digoxin) because of the potential additive effects on heart rate (see section 4.4). No data are available for concomitant use of these medicinal products with siponimod. Concomitant use of these substances during treatment initiation may be associated with severe bradycardia and heart block. Because of the potential additive effect on heart rate, treatment with siponimod should generally not be initiated in patients who are concurrently treated with these substances (see section 4.4). If treatment with siponimod is considered, advice from a cardiologist should be sought regarding the switch to non-heart-rate-lowering medicinal products or appropriate monitoring for treatment initiation.

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diltiazem (HOS-086288) siponimod (HOS-140758) sotalol (HOS-085597) quinidine (HOS-085593) digoxin (HOS-086172) calcium (HOS-085615) procainamide (HOS-086617) ivabradine (HOS-109426) amiodarone (HOS-085596) verapamil (HOS-090602)